Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME)

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule : (i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines). (ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research. M0 : during the first medical oncology visit. At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120). At the diagnosis of metastasis. At each significant event during the metastatic disease (surgery, treatment response or progression).

High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule : (i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines). (ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research. M0 : during the first medical oncology visit. At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120). At the diagnosis of metastasis. At each significant event during the metastatic disease (surgery, treatment response or progression).

Description of the metastatic events and treatments in high risk UM patients and correlation to biomarkers

Prospective collection of biological samples (circulating tumor DNA, immune-monitoring, sequencing analyses)

Prospective collection of biological samples (circulating tumor DNA, immune-monitoring, sequencing analyses)

Prospective collection of biological samples (circulating tumor DNA, immune-monitoring, sequencing analyses)

Comparison of imaging data (MRI) between the patients with and without identified biomarkers (biological tests)

Comparison of clinical data (medical patients records) between the patients with and without identified biomarkers (biological tests)

Multivariate analysis of the prognostic value of identifies biomarkers adjusted for clinical and imaging data

Multivariate analysis of the prognostic value of identifies biomarkers (biological tests) adjusted for clinical (medical patients records) and imaging data (MRI)

Inclusion Criteria: Patient aged of 18 years or more. Patient with uveal melanoma with high metastatic relapse risk defined as : T2b/c/d ou ≥ T3, or chromosom 3 or chromosom 8 abnormality by CGH array. Completion of treatment of the primary tumor ≤ 2 months. Patient able to comply with the schedule of visits and blood samples of the study. Signed informed consent form or legal representative. Exclusion Criteria: Patient without french social insurance. Any social, medical or psychological condition making the research process impossible.